100 Technology Square, 5th Floor
About Magenta Therapeutics
Magenta Therapeutics is a clinical-stage biotechnology company developing therapeutics to reset the immune system to cure more patients with devastating and life-threatening diseases. This immune reset approach can be applied through stem cell transplant to multiple diseases, including autoimmune diseases, such as multiple sclerosis and systemic sclerosis; blood cancers, such as acute myeloid leukemia; and genetic diseases, such as sickle cell disease.
Magenta's comprehensive approach to precision immune system reset will transform many aspects of the transplant process, aiming to make it safer and more effective. Our culture is fueled by a driven, passionate group of people committed making a difference, seizing opportunities to make maximum impact and pursuing progress for the patients we seek to serve.
Stock Exchange: NASDAQ
Stock Symbol: MGTA
109 articles with Magenta Therapeutics
Magenta's New Data Published in Journal Cell Show Robust Mobilization of Highly Engraftable Stem Cells in Mouse Models With Combination of GROβ and Plerixafor
The study showed that GROβ was well tolerated.
Magenta Therapeutics announced that the Company will present clinical data from its stem cell expansion program and insights into its preclinical research at the 59th annual meeting of the ASH.
Magenta Therapeutics today announced the expansion of its leadership team with the appointment of experienced industry leaders to several key roles.
Magenta Therapeutics today announced the addition of Jeff Albers, Blake Byers and Alison Lawton to its Board of Directors.
Magenta Therapeutics Announces New Clinical Data On Its Lead Expansion Clinical Program, MGTA-456, Presented At American Society Of Gene And Cell Therapy Annual Meeting
On a Roll: Magenta Therapeutics Nabs Another $50 Million, a Drug From Novartis AG and Deal With Be The Match BioTherapies
Cambridge Upstart Magenta Therapeutics Bags $48.5 Million and Will be Helmed by Former GlaxoSmithKline R&D Head